20 results about "Functional disorder" patented technology

The present application relates to a kind of pituitary adenoma simulation teaching method, one aspect, in the case of unified time axis, with the volume of pituitary adenoma as the basis, the hormone level change of corresponding hormone species and visual change condition are associated, can clearly know the curve and numerical value of GH, PRL, ACTH, cortisol and other key hormones, the condition of real-time change with tumor state change, and the real-time synchronization of visual field change and the increase and decrease of tumor size, strengthen the understanding of "space-occupied effect-dysfunction" correlation of the trainee, and the degree of oppression of pituitary adenoma to surrounding tissue is quantified by pressure sensor, the compression phenomenon of pituitary adenoma volume change is directly reflected;Another aspect, for a large number of hormone species data, through the preset data ROI search algorithm, the position of data weak fluctuation can be accurately found, and the corresponding volume change moment of pituitary adenoma helps trainee to locate quickly key time point, improves learning efficiency.

Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1) mutations, and 4-phenylbutyrate, or the pharmaceutically acceptable salt thereof, is administered at a dose of 75 mg / kg / day to 125 mg / kg / day. In another embodiment, the method comprises combined GAT-1 gene therapy combined with administration of 4-phenylbutyrate.

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction.

A dynamic multi-model counterfactual intervention prediction method for critically ill patients includes: acquiring patients' clinical medical data and preprocessing the clinical medical data; extracting features from the preprocessed clinical medical data to obtain key physiological features; processing the key physiological features using a fitted SOFA scoring algorithm to obtain the patient's organ dysfunction score; assessing the patient's risk level based on the organ dysfunction score; conducting factual intervention tests on the patient to evaluate the confidence of each LLM; performing LLM collaborative counterfactual prediction based on the patient's risk level assessment and factual intervention test to obtain counterfactual prediction results; inputting the counterfactual prediction results and clinical medical data into an LLM pool for evaluation to obtain a credibility score; constructing weights based on the credibility score; synthesizing credibility based on the weights; and generating an interpretability report. This invention effectively avoids the "illusion" and bias of single models through multi-LLM collaboration and cross-validation, and selects more credible intervention plans.

The application discloses application of a TPP2 mutant zebrafish in an ASD neurodevelopment-related disease model and belongs to the technical field of biological medicines. It is found for the first time that a TPP2 gene deletion type zebrafish has the following phenotypes: developmental retardation, developmental deformity, abnormal motor function, social dysfunction, stereotyped behavior, anxiety-like behavior and the like, has the core characteristics of ASD-related neurodevelopment-related diseases and can be used as an animal model for researching ASD neurodevelopment-related diseases, thereby providing an effective approach for diagnosing or treating ASD neurodevelopment-related diseases.

Methods of improving ARDS by regulating a stellate ganglion is provided herein. Methods of improving a hypercoagulation state are also provided by regulating the sympathetic nervous system.

Systems and methods are provided for delivering closed-loop or partially closed-loop baroreflex activation therapy (BAT) to treat conditions associated with autonomic dysfunction. A pulse generator delivers stimulation while physiological data, such as ECG, heart rate variability, bioimpedance, and physical activity levels, is collected from one or more sensors. The data is analyzed to assess autonomic nervous system activity, and stimulation parameters are dynamically adjusted in response. In some embodiments, adjustments are made on a beat-to-beat basis using ECG input. Artificial intelligence algorithms may be used to predict patient-specific responses, optimize therapy, and evaluate effectiveness. The method may further include integrating patient-reported symptoms, wirelessly transmitting data, or adjusting stimulation duty cycle based on time of day. The system may further incorporate patient-reported symptoms, a clinician dashboard for remote monitoring, and a multi-channel lead. Stimulation may be delivered non-invasively or via an implantable device.

This invention discloses a multi-dimensional quantitative assessment method and system combining meibomian gland morphology and function, belonging to the fields of ophthalmic diagnosis and artificial intelligence technology. It acquires color images of the eyelid margin, infrared images of the meibomian glands, and dynamic videos of gland expulsion upon pressure, inputting these into a dedicated AI analysis engine for processing. Employing an innovative anatomically guided backbone network and a meibomian gland region adaptive module, it achieves parallel automatic quantitative scoring across four dimensions: meibomian gland opening abnormality score, secretion characteristics score, expulsion capacity score, and morphological abnormality score based on gland segmentation loss rate. The four scores are summed to obtain a comprehensive total score, used for the graded diagnosis of meibomian gland dysfunction. By comparing changes in the patient's scores over time, it achieves macroscopic and microscopic evaluation of treatment efficacy. By integrating functional and morphological indicators into a unified automated quantitative system, it solves the problems of subjectivity and fragmentation in existing assessment methods, significantly improving the objectivity, comprehensiveness, and accuracy of diagnosis, and providing a reliable tool for individualized treatment and long-term management of MGD.

The present invention relates to a brain dysfunction and seizure detector monitor and system, and a method of detecting brain dysfunction and / or seizure of a subject. Preferably, the present invention also includes one or more seizure detection algorithms. The analysis method is specifically optimized to amplify abnormal brain activity and minimize normal background activity yielding a seizure index directly related to the current presence of ictal activity in the signal. Additionally, a seizure probability index based on historical values of the aforementioned seizure index, is derived for diagnostic purposes. The seizure probability index quantifies the probability that the patient has exhibited abnormal brain activity since the beginning of the recording. These indexes can be used in the context of emergency and / or clinical situations to assess the status and well-being of a patient's brain, or can be used to automatically administer treatment to stop the seizure before clinical signs appear.

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.

The present invention is related to a composition comprising a novel chemical compound with the chemical Name "4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol" and its use. The 4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol and related compounds are useful for treating microgravity induced damage such as skeletal muscle atrophy and dysfunction as well as cardiac dysfunction and are also useful for human diseases and conditions accompanied by significant loss of muscle mass and reduced endurance capacity, such as immobilized patients, cancer, heart failure, sepsis, diabetes mellitus, muscle genetic diseases and neurodegenerative disorders. In addition, 4-(4-((4- Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2-isopropylphenol and related compounds are useful for treating human diseases related to muscle degeneration and ageing such as sarcopenia and heart failure.

The present invention relates to: a pharmaceutical composition for preventing or treating Melas syndrome; and the like, and has been completed by identifying that an isopquinoline derivative, discovered through mitophagy activity-based screening, exhibits an excellent mitophagy promotion effect, and thus can be used as a fundamental therapeutic agent for Melas syndrome. Particularly, an isopquinoline derivative according to the present invention promotes mitophagy activity and remarkably alleviates mitochondria dysfunction in Melas syndrome cell models and in cells derived from Melas syndrome patients. Therefore, the isopquinoline derivative is expected to be effectively used, in the field of prevention, alleviation and treatment of the disease, as a fundamental therapeutic agent capable of inhibiting the cause of Melas syndrome.

Provided is a closed-loop neuromodulation system involving coordinated intervention of the brain, the spinal cord, and the lumbosacral region, which comprises a deep brain stimulation unit (401), a deep brain field potential sensing unit (402), a spinal cord stimulation unit (501), an evoked potential sensing unit (502), a control decision-making unit (10), a deep brain electrode (403), a spinal cord electrode (503), a lumbosacral electrode (602), a docking lead (601), a radio frequency transmission unit (20), and a wireless charging and power management unit (30). By constructing an application strategy for coordinated regulation of the brain, the spinal cord, and the lumbosacral region, only one neurostimulator needs to be implanted. It can be used alone for brain diseases or spinal cord-related diseases, and can also be used for coordinated stimulation for motor function reconstruction and recovery in paralyzed patients and patients with motor dysfunction, as well as for the treatment of urinary system complications. The whole system is modular in application, can be selectively used according to disease conditions, and has a wider application range.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation formation, and neuron death. Such neurodegenerative diseases include spinocerebellar ataxia type 3(SCA3).

The application discloses a sepsis organ dysfunction early warning method based on sparse data incremental coding, comprising the following steps: obtaining event sequence data and non-event sequence data of a target object, wherein the event sequence data comprises at least one of clinical diagnosis data, treatment record data and laboratory history detection data, and the non-event sequence data comprises at least past medical history data and target sign data; performing incremental coding on the event sequence data to obtain a sparse mode of the event sequence data; processing the sparse mode, the event sequence data and the non-event sequence data according to a pre-constructed early warning model to obtain a sepsis risk index of the target object; and outputting target early warning information in the case that the sepsis risk index meets preset early warning conditions.

The invention relates to medicine and can be used for training football players during the rehabilitation of functional disorders of a player's musculoskeletal system, as well as in the training of a

This invention discloses the application of ZBTB7A as a target in the preparation of products for the diagnosis or treatment of sepsis-associated encephalopathy (SAE), belonging to the field of biomedical technology. This invention confirms that ZBTB7A can serve as a diagnostic biomarker and therapeutic target for SAE, providing strong technical support for the early diagnosis and treatment of SAE. Clinical sample validation shows that the expression level of ZBTB7A in peripheral blood astrocyte-derived exosomes of SAE patients is significantly downregulated, enabling early, non-invasive auxiliary diagnosis of SAE with high clinical diagnostic efficacy. This invention clarifies that high expression of ZBTB7A can effectively inhibit the release of pro-inflammatory factors, reduce lipid peroxidation and iron overload, improve the structural and functional integrity of mitochondria, protect neuronal and synaptic structures, and significantly reverse cognitive impairment.

This invention discloses a monomeric derivative of magnolol, its preparation method, and its applications. The derivative has the structural formula shown in Formula I. This invention provides a series of novel monomeric derivatives of magnolol. Activity screening results in SH-SY5Y cells show that these derivatives can effectively antagonize FA-induced cytotoxicity. In a *C. elegans* model, they can significantly improve the survival rate of nematodes exposed to FA and reduce FA levels in nematodes, demonstrating a good FA detoxification effect. Furthermore, in an AD model of nematodes, these derivatives can delay the progression of paralysis, improve cognitive dysfunction, and reduce Aβ expression and accumulation, exhibiting significant neuroprotective effects.

Idiopathic Parkinson's disease (iPD) is a multi-system disorder, and the debilitating motor stage of iPD can be preceded for years by a prodromal stage characterized by non-motor symptoms like REM sleep behavior disorder (RBD) and gastrointestinal symptoms. Widespread immune dysregulation has been reported in clinically diagnosed iPD, but the existence of immune deficits during the prodromal stage has yet to be thoroughly investigated. Here, it was shown that multiple stages of iPD, including the pre-motor prodromal stage, can be stratified according to the immuno-metabolic response to stimulation of peripheral blood immune cells ex vivo. Peripheral blood monocytes from RBD patients displayed increased stimulation-dependent secretion of inflammatory cytokines, including TNF, IL-1β, and IL-8, which peaks in the prodromal stage and successively diminishes as PD progresses. Furthermore, T lymphocyte mitochondrial health was correlated with stimulation-evoked cytokine secretion across patients with RBD, early-stage iPD, and moderate-stage iPD. The results disclosed here have broad implications for mechanistic understanding of how peripheral inflammation may drive disease progression, and it reveals novel biomarkers to enable patient stratification and progression monitoring for clinical trials based on immune endophenotypes.

Provided are methods for treating brain tumors, characterized by an IDH1 and / or IDH2 mutation, with vorasidenib, in patients with hepatic impairment.